Trial · NCT04382768
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in the scale of ordinary COVID results at 7, 14 and 28 days in patients with acute respiratory infection, induced by SARS-CoV-2, treated with inhaled Ibuprofen. | 7, 14 and 28 days | Time to clinical improvement: defined as time from inhaled Ibuprofen first dose to an improvement of three points from the status on a seven-category ordinary scale |
| Primary | Change to Negativization of the swab to the following treatment points on day 7, day 14, 21 and 28 after treatment with inhaled Ibuprofen. | 7, 14 and 28 days | Negativization of two consecutive pharyngo-nasal swab 24-72 hrs apart |
| Secondary | Chage in length of Hospital stay | 28 days | |
| Secondary | Chage in duration of ventilation | 28 days | |
| Secondary | Chage in length of Critical Care stay | 28 days | |
| Secondary | Average score of National Early Warning (NEWS2) between days 1, 7, 14 and 28. | 1, 7, 14 and 28 | NEWS2 score 20 points is the maximum and indicates that the patient needs emergent assessment by a clinical team or critical care team and usually transfer to higher level of care. |
| Secondary | Average change in quick sepsis-related organ failure assessment score (qSOFA) score between day 1, 7, 14 and 28. | 1, 7, 14 and 28 days | qSOFA, score for sepsis, a maximum value of 3 indicates high risk qSOFA Scores 2-3 are associated with a 3- to 14-fold increase in in-hospital mortality. Assess for evidence of organ dysfunction with blood testing including serum lactate and calculation of the full SOFA Score. Patients meeting these qSOFA criteria should have infection considered even if it was previously not. |
| Secondary | Time from first dose to conversion to normal or mild pneumonia | 28 days | |
| Secondary | Antibiotic requirement | 28 days | |
| Secondary | Glucocorticoids requirement | 28 days | |
| Secondary | Incidence of adverse event | 28 days | |
| Secondary | Incidence of serious adverse event | 28 days | |
| Secondary | Number of deaths from any cause at 28 days | 28 days | |
| Secondary | Lymphocyte count | 28 days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04382768/registered